Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma

Published by: BioSeeker Group AB

Published: Feb. 6, 2008 - 540 Pages

Table of Contents

Executive Summary

2 Methodologies

3 Table of Contents

3.1 List of Tables

3.2 List of Boxes

3.3 List of Figures

4 Introduction to Apoptotic Drugs in Oncology

5 Apoptopic Drug Compound Types and Sub-cellular Localizations of Targets

6 The Cancer Genome Project and Apoptopic Drug Targets

6.1 Apoptopic Drug Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

7 Protein Expression Profiles of Apoptopic Drug Targets in Human

7.1 Expression in Normal Tissues and Cancer Tissues

7.2 Expression in Human Cancer Cell Lines and Primary Cells

8 Pathway Analysis of Drug Targets of Apoptopic Drugs

9 Protein-Protein Interactions Between Identified Apoptopic Drug Targets

10 Available Biological Structure Data on Apoptopic Drug Targets

11 Drug Target Profiles of Apoptopic Drug Targets in Oncology

11.1.1 Auxiliary transport protein activity

11.1.2 Carboxy-lyase activity

11.1.3 Catalytic activity

11.1.4 Cell adhesion molecule activity

11.1.5 Chaperone activity

11.1.6 Complement activity

11.1.7 Cysteine-type peptidase activity

11.1.8 Cytokine activity

11.1.9 DNA topoisomerase activity

11.1.10 Glutathione transferase activity

11.1.11 Hormone activity

11.1.12 Hydrolase activity

11.1.13 Intracellular ligand-gated ion channel activity

11.1.14 Kinase activity

11.1.15 Kinase regulator activity

11.1.16 Ligase activity

11.1.17 Lipid kinase activity

11.1.18 Metallopeptidase activity

11.1.19 Molecular function unknown

11.1.20 Motor activity

11.1.21 Oxidoreductase activity

11.1.22 Peptide hormone

11.1.23 Peroxidase activity

11.1.24 Protein binding

11.1.25 Protein serine/threonine kinase activity

11.1.26 Protein threonine/tyrosine kinase activity

11.1.27 Protein-tyrosine kinase activity

11.1.28 Receptor activity

11.1.29 Receptor binding

11.1.30 Receptor signaling complex scaffold activity

11.1.31 Receptor signaling protein serine/threonine kinase activity

11.1.32 RNA binding

11.1.33 Structural constituent of cytoskeleton

11.1.34 Superoxide dismutase activity

11.1.35 T cell receptor activity

11.1.36 Transcription factor activity

11.1.37 Transcription regulator activity

11.1.38 Transferase activity

11.1.39 Translation regulator activity

11.1.40 Transmembrane receptor activity

11.1.41 Transmembrane receptor protein tyrosine kinase activity

11.1.42 Transporter activity

12 Apoptopic Drug Target Mix by Development Stage

13 Apoptopic Drug Target Mix by Cancer Indication

13.1 Basal Cell Cancer

13.2 Biliary Cancer

13.3 Bladder Cancer

13.4 Bone Cancer

13.5 Brain Cancer

13.6 Breast Cancer

13.7 Carcinoid Tumor

13.8 Cervical Cancer

13.9 Chemotherapy-induced Neutropenia

13.10 Colorectal Cancer

13.11 Endometrial Cancer

13.12 Fallopian Tube Cancer

13.13 Gastrointestinal Cancer

13.13.1 Gastrointestinal Stomach Cancer

13.13.2 Gastrointestinal Stromal Cancer

13.14 Head and Neck Cancer

13.15 Leukemia

13.15.1 Acute Lymphocytic Leukemia

13.15.2 Acute Myelogenous Leukemia

13.15.3 Chronic Lymphocytic Leukemia

13.15.4 Chronic Myelogenous Leukemia

13.16 Liver Cancer

13.17 Lung Cancer

13.17.1 Non-Small Cell Lung Cancer

13.17.2 Small Cell Lung Cancer

13.18 Lymphoma

13.18.1 B-cell Lymphoma

13.18.2 Hodgkin's Lymphoma

13.18.3 non-Hodgkin's Lymphoma

13.18.4 T-cell Lymphoma

13.19 Melanoma

13.20 Mesothelioma

13.21 Myelodysplastic Syndrome

13.22 Myeloma

13.23 Nasopharyngeal Cancer

13.24 Oesophageal Cancer

13.25 Oral Cancer

13.26 Ovarian Cancer

13.27 Pancreatic Cancer

13.28 Peritoneal Cancer

13.29 Prostate Cancer

13.30 Renal Cancer

13.31 Sarcoma

13.31.1 Leiomyo Sarcoma

13.32 Squamous Cell Cancer

13.33 Testicular Cancer

13.34 Thymoma Cancer

13.35 Thyroid Cancer

14 Apoptopic Drugs and their Targets by Companies

14.1 Australia

14.2 Canada

14.3 China

14.4 Denmark

14.5 Germany

14.6 Israel

14.7 Japan

14.8 South Korea

14.9 Spain

14.10 Switzerland

14.11 Taiwan

14.12 United Kingdom

14.13 USA

15 Lung cancer: An Introduction

15.1 Current Treatment Strategies

15.2 Disease Definition

15.3 Etiology & Pathophysiology

15.4 Prognosis

15.5 Epidemiology

16 Progress in Current Lung Cancer Treatment Strategies

16.1 Improvements Adding microtubule Inhibitor

16.2 Improvement of Disease Related Symptoms in Elderly Patients

16.3 Toxicity Profile Favored

16.4 A New Formula

16.5 Monotherapy?

16.6 Failed to Demonstrate a Survival Advantage

16.7 Reduction in Mortality Risk

17 Key Drug Strategies in Lung Cancer

17.1 Apoptosis

17.2 Antiangiogenesis and Antivascular Agents

17.2.1 EGFR and VEGFR as target

17.2.2 Immunotherapy

18 Competitive Landscape in Lung Cancer Drug Development: The Late Stage Pipeline

18.1 Grade 4 Adverse Events

18.2 No New Remarks

18.3 No Significant Effect on Overall Survival

18.4 Bristol Myers Squibb Entered into an Agreement

18.5 Many Uncertainties Remain

18.6 Development Terminated

18.7 Continuing Enrollment

18.8 Apoptotic Inducer

18.9 Fully-Human Monoclonal Antibody

18.10 Eagerly Awaiting Data

18.11 Mutations and Response

18.12 Statistically and Clinically Significant Survival Advantage

18.13 Anti-Idiotypic Monoclonal Antibody

18.14 Shift in the Development Focus

18.15 Sensitizer

18.16 Treatment in Earlier-Stage Cancer Could be More Effective

18.17 Discontinued Radiosensitizer

18.18 Improvement in Chemoradiotherapy

18.19 Progress on HDAC Inhibitor

18.20 Progress Analysis Carboxyamidotriazole

18.21 Chemotherapy naïve subjects

19 Etiology and Pathophysiology of Melanoma

20 Current Melanoma Treatment Strategies

20.1 An Overview

20.2 Cytotoxic Drugs

20.2.1 Dacarbazine

20.2.2 Cisplatin

20.2.3 Carboplatin

20.2.4 Carmustine

20.2.5 Melphalan

20.2.6 Paclitaxel

20.2.7 Tamoxifen

20.2.8 Temozolomide

20.2.9 Vinblastine/Vinorelbine

20.3 Biological treatments

20.3.1 Intron A

20.3.2 Virulizin

20.3.3 Melacine

20.3.4 Alfanative (Multiferon)

20.3.5 Proleukin or (Macrolin)

20.3.6 Enhanzyn

20.3.7 M-VAX

20.4 Other

20.4.1 Ceplene Maxamine

21 Key Melanoma Therapy Strategies

21.1 Immunotherapy

21.2 Anti-angiogenesis

21.3 Apoptotic Induction

21.4 Gene Therapy

22 Current Melanoma Drug Development: Late Stage Pipeline

22.1 Immunotherapy

22.1.1 Oncophage

22.1.2 Canvaxin

22.1.3 GMK

22.1.4 MDX-010

22.1.5 OncoVax

22.1.6 ALLOVECTIN-7

22.1.7 Peginterferon alfa-2b

22.2 Anti-angiogenesis

22.2.1 Lenalidomide

22.3 Apoptotic Inducers

22.3.1 Genasense

22.4 Inhibiting Cell Growth

22.4.1 Temozolomide

23 Current Melanoma Drug Development: Early Stage Pipeline

23.1 Immunotherapy

23.1.1 INGN 241

23.1.2 QS-21

23.1.3 Talabostat

23.1.4 SB 249553

23.1.5 GVAX

23.1.6 GV 1001

23.1.7 Dexosome

23.1.8 Uvidem

23.1.9 NY-ESO-1 ISCOMS

23.1.10 NOVOVAC-M1

23.1.11 Oxxon Vaccine

23.1.12 Therion’s Melanoma Vaccine

23.1.13 ImmunoVex trimelan

23.1.14 OncoVEXGM-CSF

23.1.15 Zadaxin

23.1.16 Alvac-Mage1/Mage3

23.1.17 Iboctadekin

23.1.18 ProMune

23.1.19 BAY 504798

23.1.20 EMD 273063

23.2 Antiangiogenesis

23.2.1 Sorafenib

23.2.2 Vitaxin

23.2.3 Avastin

23.2.4 PI 88

23.3 Apoptotic Inducers

23.3.1 Didemnin B

23.3.2 KOS 953

23.4 Small Molecules Inhibiting Cell Growth

23.4.1 Pivanex

23.4.2 Karenitecin

23.4.3 Lomeguatrib

23.4.4 PD 0325901

23.4.5 SB 715992

23.4.6 INO 1001

23.4.7 CP 4055

23.5 Other Biological Drugs

23.5.1 AP 12009

23.5.2 Ecromeximab

23.5.3 ILX 651

23.5.4 Kahalalide F

23.5.5 ABX MA1

23.5.6 MJV 101

23.5.7 A Russian Melanoma Vaccine

23.5.8 Elea Vaccine

23.5.9 F 50040

24 Appendix 1. Treatment Guide Lines Lung Cancer*

24.1 References

25 Appendix 2: Selected Company Profiles

25.1 Abgenix

25.2 Aphton

25.3 AstraZeneca

25.4 Bristol-Myers Squibb

25.5 Eli Lilly

25.6 Genentech

25.7 Genta

25.8 GlaxoSmithKline

25.9 ImClone

25.10 ISIS Pharmaceuticals

25.11 Ligand Pharmaceuticals

25.12 OSI Pharmaceuticals

25.13 Pfizer

25.14 Pharmacyclics

25.15 Sanofi- Aventis

25.16 Telik

26 Appendix 3 Progress profiles on approved drugs

26.1 Docetaxel

26.2 Vinorelbine

26.3 Gemcitabine

26.4 Paclitaxel

26.5 Pemetrexed

26.6 Gefitinib

26.7 Erlotinib

27 Appendix 4: Treatment Guide Lines Melanoma

28 Disclaimer

29 Drug Index

30 Company Index

3.1 List of Tables

Table 1: Compound Type Versus Primary and Alternate Localization of Drug Target

Table 2: Drug Targets of Apoptopic Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census

Table 3: Available Protein Expression Profiles of Apoptopic Drug Targets

Table 4: Pathway Summary

Table 5: Drug Targets Without any Identified Assigned Pathways

Table 6: Pathway Profile According to BioCarta of the Drug Targets Belonging to Apoptopic Drugs

Table 7: Drug Targets Belonging to Apoptopic Pathways According to BioCarta

Table 8: Pathway Profile According to KEGG of the Drug Targets Belonging to Apoptopic Drugs

Table 9: Drug Targets within the Apoptosis Pathway According to KEGG

Table 10: Apoptopic Drugs Targeting Major Singaling Pathways

Table 11: Protein-Protein Interactions Between Identified Apoptopic Drug Targets

Table 12: Targets of Apoptopic Drugs without Protein-Protein Interaction with other Drug Targets

Table 13: Number of Available Biological Structures on Apoptopic Drug Targets

Table 14: Overview of Drug Target Profile Themes

Table 15: Fall Out in Terms of the Number of Drug Target Mixes, Drugs, and Developmental Projects by Developmental Stage

Table 16: Apoptopic Drug Target Mixes by Development

Table 17: Number of Unique Apoptopic Drug Target Mixes Reported by Cancer Indication

Table 18: Apoptopic Drug Target Mix for the Treatment of Basal Cell Cancer According to the Compound Type and Developmental Stage of Drug

Table 19: Apoptopic Drug Target Mix for the Treatment of Biliary Cancer According to the Compound Type and Developmental Stage of Drug

Table 20: Apoptopic Drug Target Mix for the Treatment of Bladder Cancer According to the Compound Type and Developmental Stage of Drug

Table 21: Apoptopic Drug Target Mix for the Treatment of Bone Cancer According to the Compound Type and Developmental Stage of Drug

Table 22: Apoptopic Drug Target Mix for the Treatment of Brain Cancer According to the Compound Type and Developmental Stage of Drug

Table 23: Apoptopic Drug Target Mix for the Treatment of Breast Cancer According to the Compound Type and Developmental Stage of Drug

Table 24: Apoptopic Drug Target Mix for the Treatment of Carcinoid Tumor According to the Compound Type and Developmental Stage of Drug

Table 25: Apoptopic Drug Target Mix for the Treatment of Cervical Cancer According to the Compound Type and Developmental Stage of Drug

Table 26: Apoptopic Drug Target Mix for the Treatment of Chemotherapy-induced Neutropenia According to the Compound Type and Developmental Stage of Drug

Table 27: Apoptopic Drug Target Mix for the Treatment of Colorectal Cancer According to the Compound Type and Developmental Stage of Drug

Table 28: Apoptopic Drug Target Mix for the Treatment of Endometrial Cancer According to the Compound Type and Developmental Stage of Drug

Table 29: Apoptopic Drug Target Mix for the Treatment of Fallopian Tube Cancer According to the Compound Type and Developmental Stage of Drug

Table 30: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Cancer According to the Compound Type and Developmental Stage of Drug

Table 31: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Stomach Cancer According to the Compound Type and Developmental Stage of Drug

Table 32: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Stromal Cancer According to the Compound Type and Developmental Stage of Drug

Table 33: Apoptopic Drug Target Mix for the Treatment of Head and Neck Cancer According to the Compound Type and Developmental Stage of Drug

Table 34: Apoptopic Drug Target Mix for the Treatment of Leukemia (general) According to the Compound Type and Developmental Stage of Drug

Table 35: Apoptopic Drug Target Mix for the Treatment of Acute Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug

Table 36: Apoptopic Drug Target Mix for the Treatment of Acute Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug

Table 37: Apoptopic Drug Target Mix for the Treatment of Chronic Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug

Table 38: Apoptopic Drug Target Mix for the Treatment of Chronic Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug

Table 39: Apoptopic Drug Target Mix for the Treatment of Liver Cancer According to the Compound Type and Developmental Stage of Drug

Table 40: Apoptopic Drug Target Mix for the Treatment of Lung Cancer (general) According to the Compound Type and Developmental Stage of Drug

Table 41: Apoptopic Drug Target Mix for the Treatment of Non-Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug

Table 42: Apoptopic Drug Target Mix for the Treatment of Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug

Table 43: Apoptopic Drug Target Mix for the Treatment of Lymphoma (general) According to the Compound Type and Developmental Stage of Drug

Table 44: Apoptopic Drug Target Mix for the Treatment of B-cell Lymphoma According to the Compound Type and Developmental Stage of Drug

Table 45: Apoptopic Drug Target Mix for the Treatment of Hodgkin’s Lymphoma According to the Compound Type and Developmental Stage of Drug

Table 46: Apoptopic Drug Target Mix for the Treatment of non-Hodgkin’s Lymphoma According to the Compound Type and Developmental Stage of Drug

Table 47: Apoptopic Drug Target Mix for the Treatment of T-cell Lymphoma According to the Compound Type and Developmental Stage of Drug

Table 48: Apoptopic Drug Target Mix for the Treatment of Melanoma According to the Compound Type and Developmental Stage of Drug

Table 49: Apoptopic Drug Target Mix for the Treatment of Mesothelioma According to the Compound Type and Developmental Stage of Drug

Table 50: Apoptopic Drug Target Mix for the Treatment of Myelodysplastic Syndrome According to the Compound Type and Developmental Stage of Drug

Table 51: Apoptopic Drug Target Mix for the Treatment of Myeloma According to the Compound Type and Developmental Stage of Drug

Table 52: Apoptopic Drug Target Mix for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Drug

Table 53: Apoptopic Drug Target Mix for the Treatment of Oesophageal Cancer According to the Compound Type and Developmental Stage of Drug

Table 54: Apoptopic Drug Target Mix for the Treatment of Oral Cancer According to the Compound Type and Developmental Stage of Drug

Table 55: Apoptopic Drug Target Mix for the Treatment of Ovarian Cancer According to the Compound Type and Developmental Stage of Drug

Table 56: Apoptopic Drug Target Mix for the Treatment of Pancreatic Cancer According to the Compound Type and Developmental Stage of Drug

Table 57: Apoptopic Drug Target Mix for the Treatment of Peritoneal Cancer According to the Compound Type and Developmental Stage of Drug

Table 58: Apoptopic Drug Target Mix for the Treatment of Prostate Cancer According to the Compound Type and Developmental Stage of Drug

Table 59: Apoptopic Drug Target Mix for the Treatment of Renal Cancer According to the Compound Type and Developmental Stage of Drug

Table 60: Apoptopic Drug Target Mix for the Treatment of Sarcoma (general) According to the Compound Type and Developmental Stage of Drug

Table 61: Apoptopic Drug Target Mix for the Treatment of Leiomyo Sarcoma According to the Compound Type and Developmental Stage of Drug

Table 62: Apoptopic Drug Target Mix for the Treatment of Squamous Cell Cancer According to the Compound Type and Developmental Stage of Drug

Table 63: Apoptopic Drug Target Mix for the Treatment of Testiculat Cancer According to the Compound Type and Developmental Stage of Drug

Table 64: Apoptopic Drug Target Mix for the Treatment of Thymoma Cancer According to the Compound Type and Developmental Stage of Drug

Table 65: Apoptopic Drug Target Mix for the Treatment of Thyroid Cancer According to the Compound Type and Developmental Stage of Drug

Table 66: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Australia

Table 67: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Canada

Table 68: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in China

Table 69: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Denmark

Table 70: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Germany

Table 71: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Israel

Table 72: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Japan

Table 73: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in South Korea

Table 74: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Spain

Table 75: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Switzerland

Table 76: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Taiwan

Table 77: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in United Kingdom

Table 78: Apoptopic Drugs with Target Mix and Developmental Projects by Company in USA

Table 64: Chemotherapeutic drugs for treatment of NSCLC

Table 65. Near Term Approved Drugs for the Treatment of NSCLC

Table 66: Chemotherapy Drugs off Patent

Table 67 Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways.

Table 68 VTA agents under development

Table 69 EGFR or VEGFR inhibitors

Table 70: FMS-like tyrosine kinases and their Synonyms

Table 71: Fms-related Tyrosine Kinase Targets in Development

Table 72: Protein Kinase Targets in Clinical Trials for Lung Cancer

Table 73 Cancer immunotherapy strategies

Table 74 Recently presented studies Lapatinib

Table 75 Recently presented studies ZD-

Table 76 Recently presented studies vinflunine

Table 77 Recently presented studies Panitumumab

Table 78 Recently presented studies Genasense

Table 79 Recently presented studies cetuximab

Table 80 Recently presented studies bevacizumab

Table 81 Recently presented studies bexarotene

Table 82 Recently presented studies Xcytrin

Table 83: Critical Risk Factors for Development of Melanoma

Table 84: Definition and Description of Stages of Melanoma

Table 85: Prognosis of the 4 Stages of Malignant Melanoma

Table 86: Current Cytotoxic Drugs for the Treatment of Melanoma

Table 87: Progress Profile Dacarbazine

Table 88: Progress Profile Cisplatin

Table 89: Progress Profile Carboplatin

Table 90: Progress Profile Carmustine

Table 91: Progress Profile Melphalan

Table 92: Progress Profile Paclitaxel

Table 93: Progress Profile Tamoxifen

Table 94: Progress Profile Temozolomide

Table 95: Progress Profile Vinblastine/Vinorelbine

Table 96: Progress Profile Interferon alfa-2b

Table 97: Development Milestones- Virulizin

Table 98: Development Milestones - Melacine

Table 99: Development Milestones - Alfanative

Table 100: Development Milestones - Proleukin

Table 101: Deployed Strategies for Blocking Angiogenesis

Table 102: Phase III Randomized Studies of Melanoma Vaccines.

Table 103: Tumor antigen based vaccines

Table 104: In vivo Gene Therapy

Table 105: Cell Therapy Based Platform in Pipeline as Potential Treatment of Melanoma

Table 106: Ex vivo gene therapy loading of antigen presenting cells

Table 107: Overview of Immunostimulants in Development based on Type

Table 108: Overview of Immuno-Biologicals

Table 109: Overview of Gene Therapy Drugs for Immunostimulation

Table 110: MDX-010’s Collaborative History and Landscape

Table 111: Anti-angiogenisis Drugs under Development

Table 112: Overview Apoptopic Inducer Drugs

Table 113: Overview of Small Molecule Drugs

Table 114:Selected Regulatory Progress of Sorafenib

Table 115: Selected Regulatory Progress of Didemin B

Table 116: Overview of Various Biological Drugs in Development for Melanoma

3.2 List of Boxes

Box 1: Quick facts on Docetaxel

Box 2: Scientific Data on Docetaxel

Box 3: Quick Facts - Vinorelbine

Box 4: Scientific Data on Vinorelbine

Box 5: Quick Facts - Gemcitabine

Box 6: Scientific Data on gemcitabine

Box 7: Quick Facts - pemetrexed

Box 8: Scientific Data on Pemetrexed

Box 9: Quick Facts - Gefitinib

Box 10: Scientific Data on Gefitinib

Box 11: Quick Facts - Erlotinib

Box 12: Quick Facts - Enhanzyn

Box 13: Quick Facts - M-VAX

Box 14: M-VAX - Business & Market Bakground

Box 15: Mechanisms which Tumor Cells use to Evade an Immune Reaction

Box 16: Introgen’s INGN 241 Shows Vaccine Properties

Box 17: Quick Facts - Oncophage

Box 18: Oncophage - Designation and Status

Box 19: Quick Facts - Canvaxin

Box 20: Canvaxin - Designation and Status

Box 21: CancerVax Milestone payment

Box 22: Quick Facts - GM2-KLH Vaccine

Box 23: Progenics Reaquires Rights to Vaccine

Box 24: Completed Melanoma Phase III trials

Box 25: Quick Facts - MDX-010

Box 26: Quick Facts -OncoVax

Box 27: Quick Facts - ALLOVECTIN-7

Box 28: Quick Facts - Peginterferon alfa-2b

Box 29: Introgen’s INGN 241 Shows Anti-angiogenesis Properties

Box 30: Quick Facts - Lenalidomide

Box 31: Quick Facts - Oblimersen

Box 32: Quick Facts - Temozomide

Box 33: Molecular Pathways Underlying the Activity of Temozolomide’s Anti-Cancer Therapy

Box 34: Regulatory Progress

Box 35: Quick Facts - INGN 241

Box 36: Molecular Pathways Underlying Activity of Introgen's INGN 241 Anti-Cancer Therapy

Box 37: Quick Facts - QS-21

Box 38: Quick Facts - Talabostat

Box 39: Quick Facts - SB 249553

Box 40: Quick Facts - GVAX

Box 41: Agreement Japan Tobacco and Cell Genesys

Box 42: Predicted launch of GVAX

Box 43: Quick Facts - GV 1001

Box 44: Quick Facts - Dexosome

Box 45: Important Milestones and License Fees

Box 46: Quick Facts - Uvidem

Box 47: Agreements Between Sanofi-Aventis and IDM

Box 48: Quick Facts - NY-ESO-1 ISCOMS

Box 49: NY-ESO-1 and ISCOMATRIX

Box 50: Quick Facts - NovoVac-M1

Box 51: Quick Facts - Oxxon vaccine

Box 52: Quick Facts - Therion’s Melanoma Vaccine

Box 53: Quick Facts - ImmunoVEX trimelan

Box 54: Quick Facts - OncoVEX GM-CSF

Box 55: Quick Facts - ZADAXIN

Box 56: Developmental History Thymosin alpha1

Box 57: Quick Facts - Alvac-Mage1/Mage3

Box 58: Quick Facts - iboctadekin

Box 59: Quick Facts - PF-3512676

Box 60: Quick Facts - BAY-504798

Box 61: Quick Facts - EMD-273063

Box 62: Quick Facts - Sorefenib

Box 63: Quick Facts - Vitaxin

Box 64: Quick Facts . Bevacizumab

Box 65: Quick Facts - PI88

Box 66: Quick Facts - Didemnin B

Box 67: Quick Facts - KOS 953

Box 68: Quick Facts - Pivanex

Box 69: Quick Facts - Karenitecin

Box 70: Company Statement

Box 71: Quick Facts - Lomeguatrib

Box 72: Quick Facts - PD 0325901

Box 73: Quick Facts - SB 715992

Box 74: Quick Facts - INO 1001

Box 75: Quick Facts - CP 4055

Box 76: Quick Facts - AP 12009

Box 77: Quick Facts - Ecromeximab

Box 78: Quick Facts - ILX 651

Box 79: Quick Facts - Kahalalide F

Box 80: Quick Facts - ABX MA1

Box 81: Quick Facts - MJV 101

Box 82: Quick Facts - Russian Melanoma Vaccine

Box 83: Quick Facts - N-Acetyl-GM3 ganglioside

Box 84: Quick Facts - F

Box 85: KpOmpA Technology

3.3 List of Figures

Figure 1: Distribution of Compound Types Among Apoptopic Drugs

Figure 2: Primary Sub-cellular Localization of Drug Targets

Abstract

• A hundred different tables. Includes more than 1,500 active links to related resources on the Internet
• 114 apoptopic drugs, under development by 87 investigators, are included, covering more than 430 developmental projects in cancer
• 119 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other apoptopic drug targets, linked cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.
• 90 Unique drug target combinations of apoptopic drugs
• 452 protein-protein interactions among apoptopic drug targets
• Extensive pathway analysis of drug targets
• The risk of malignant melanoma has more than doubled in the past decade.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.